by [email protected] | May 1, 2019 | Cardiovascular, Publication
Abstract Objective: To compare the risk and cost of stroke/systemic embolism (SE) and major bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular atrial fibrillation (NVAF) patients. Methods: Patients (≥65 years) initiating warfarin or...
by [email protected] | Apr 30, 2019 | Cardiovascular, Publication
Abstract Authors: Wang L, Baser O, Wells P, Peacock WF, Coleman CI, Fermann GJ, Schein J, Crivera C. Purpose: Due to limited evidence on the impact of rivaroxaban in clinical practice, we compared the effectiveness of rivaroxaban vs standard of care (SOC) among...
by [email protected] | Apr 29, 2019 | Cardiovascular, Publication
Abstract The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin. This retrospective study used four large US claims databases...
by [email protected] | Apr 28, 2019 | Cardiovascular, Publication, Pulmonary
Abstract Authors: Kohn CG, Weeda ER, Kumar N, Wells PS, Peacock WF, Fermann GJ, Wang L, Baser O, Schein JR, Crivera C, Coleman CI. The In-hospital Mortality for PulmonAry embolism using Claims daTa (IMPACT) rule can accurately identify pulmonary embolism (PE) patients...
by [email protected] | Apr 27, 2019 | Cardiovascular, Publication
Abstract Authors: Lip GYH, Keshishian A, Kamble S, Pan X, Mardekian J, Horblyuk R, Hamilton M. In addition to warfarin, there are four non-vitamin K antagonist oral anticoagulants (NOACs) available for stroke prevention in non valvular atrial fibrillation (NVAF)....
by [email protected] | Apr 26, 2019 | Cardiovascular, Publication
Abstract Objective: To quantify and compare hospital length of stay (LOS) and costs between hospitalized non-valvular atrial fibrillation (NVAF) patients treated with either apixaban or warfarin via a large claims database. Methods: Adult patients hospitalized with AF...
